A high level of cholesterol puts millions of people worldwide at risk of heart disease and stroke every day. Now, a new drug could provide strong protection against these risks, by a therapy that specifically targets lipoprotein(a) levels is on the horizon. In a clinical trial, the drug, which obstructs the body’s strength to make the protein, decreased people’s levels of lipoprotein(a) by as much as 80 percent.To decide if the drug is useful at lessening the risk of heart attack and stroke, a phase III clinical trial, run by Novartis Pharmaceuticals of Basel, Switzerland, has started selecting participants. If that trial is successful, the researchers will look for commercial partners to take it forward.
Disclaimer: The above article has been aggregated by a computer program and summarised by an Steamdaily specialist. You can read the original article at sciencenews
